Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers for Psychosis, Are We There Yet? Umbrella Review of 1478 Biomarkers

  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Estradé, Andrés|||0000-0001-6871-5932
  • Solanes, Aleix|||0000-0002-2491-200X
  • Ramella-Cravaro, Valentina
  • Garcia-Leon, Maria Angeles
  • Diego-Adeliño, Javier de|||0000-0001-9708-2441
  • Molins, Conrad
  • Fung, Eric
  • Valentí, Marc
  • Anmella, Gerard|||0000-0002-6798-4054
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Oliver, Dominic|||0000-0002-8920-3407
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
This umbrella review aims to comprehensively synthesize the evidence of association between peripheral, electrophysiological, neuroimaging, neuropathological, and other biomarkers and diagnosis of psychotic disorders. We selected systematic reviews and meta-analyses of observational studies on diagnostic biomarkers for psychotic disorders, published until February 1, 2018. Data extraction was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Evidence of association between biomarkers and psychotic disorders was classified as convincing, highly suggestive, suggestive, weak, or non-significant, using a standardized classification. Quality analyses used the Assessment of Multiple Systematic Reviews (AMSTAR) tool. The umbrella review included 110 meta-analyses or systematic reviews corresponding to 3892 individual studies, 1478 biomarkers, and 392 210 participants. No factor showed a convincing level of evidence. Highly suggestive evidence was observed for transglutaminase autoantibodies levels (odds ratio [OR] = 7.32; 95% CI: 3.36, 15.94), mismatch negativity in auditory event-related potentials (standardized mean difference [SMD] = 0.73; 95% CI: 0.5, 0.96), P300 component latency (SMD = -0.6; 95% CI: -0.83, -0.38), ventricle-brain ratio (SMD = 0.61; 95% CI: 0.5, 0.71), and minor physical anomalies (SMD = 0.99; 95% CI: 0.64, 1.34). Suggestive evidence was observed for folate, malondialdehyde, brain-derived neurotrophic factor, homocysteine, P50 sensory gating (P50 S2/S1 ratio), frontal N -acetyl-aspartate, and high-frequency heart rate variability. Among the remaining biomarkers, weak evidence was found for 626 and a non-significant association for 833 factors. While several biomarkers present highly suggestive or suggestive evidence of association with psychotic disorders, methodological biases, and underpowered studies call for future higher-quality research.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miguel
  • Bioque, Miquel
  • Morén, Constanza
  • Pina-Camacho, Laura
  • Díaz-Caneja, Covadonga M.
  • Zorrilla, Iñaki
  • Corres, Edurne Garcia
  • De-La-Camara, Concepción
  • Barcones, Fe
  • Escarti, María José
  • Aguilar, Eduardo Jesus
  • Legido, Teresa
  • Martin, Marta
  • Verdolini, Norma
  • Martinez-Aran, Anabel
  • Baeza, Immaculada
  • de la Serna, Elena
  • Contreras, Fernando
  • Bobes, Julio
  • García-Portilla, María Paz
  • Sanchez-Pastor, Luis
  • Rodriguez-Jimenez, Roberto
  • Usall, Judith
  • Butjosa, Anna
  • Salgado-Pineda, Pilar
  • Salvador, Raymond
  • Pomarol-Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18–24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

  • Radua, Joaquim|||0000-0003-1240-5438
  • Vieta, Eduard|||0000-0002-0548-0053
  • Shinohara, Russell
  • Kochunov, Peter
  • Quidé, Yann|||0000-0002-8569-7139
  • Green, Melissa J.
  • Weickert, Cynthia S.
  • Weickert, Thomas
  • Bruggemann, Jason
  • Kircher, Tilo|||0000-0002-2514-2625
  • Nenadić, Igor|||0000-0002-0749-7473
  • Cairns, Murray J.
  • Seal, Marc
  • Schall, Ulrich
  • Henskens, Frans
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Mowry, Bryan
  • Pantelis, Christos|||0000-0002-9565-0238
  • Lenroot, Rhoshel
  • Cropley, Vanessa
  • Loughland, Carmel
  • Scott, Rodney
  • Wolf, Daniel H.
  • Satterthwaite, Theodore D.|||0000-0001-7072-9399
  • Tan, Yunlong
  • Sim, Kang|||0000-0003-3209-9626
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Solanes, Aleix|||0000-0002-2491-200X
  • Albajes-Eizagirre, Anton
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Sarro, Salvador
  • Giorgio, Annabella Di
  • Bertolino, Alessandro
  • Stäblein, Michael
  • Oertel, Viola
  • Knöchel, Christian
  • Borgwardt, Stefan
  • du Plessis, Stefan
  • Yun, Je-Yeon|||0000-0002-5531-2410
  • Kwon, Jun Soo|||0000-0002-1060-1462
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Hahn, Tim|||0000-0002-8929-4134
  • Grotegerd, Dominik
  • Alloz, Clara
  • Arango, Celso|||0000-0003-3382-4754
  • Janssen, Joost|||0000-0001-7613-2067
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Jiang, Wenhao
  • Calhoun, Vince
  • Ehrlich, Stefan|||0000-0003-2132-4445
  • Yang, Kun
  • Cascella, Nicola G.
  • Takayanagi, Yoichiro
  • Sawa, Akira
  • Tomyshev, Alexander
  • Lebedeva, Irina
  • Kaleda, Vasily
  • Kirschner, Matthias
  • Hoschl, Cyril
  • Tomecek, David
  • Skoch, Antonin
  • van Amelsvoort, Therese
  • Bakker, Geor
  • James, Anthony|||0000-0002-2742-8328
  • Preda, Adrian
  • Weideman, Andrea
  • Stein, Dan J.|||0000-0001-7218-7810
  • Howells, Fleur
  • Uhlmann, Anne|||0000-0002-1753-7811
  • Temmingh, Henk
  • López-Jaramillo, Carlos
  • Díaz-Zuluaga, Ana M..
  • Fortea, Lydia|||0000-0001-6778-2316
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
  • Jahanshad, Neda|||0000-0003-4401-8950
  • Thompson, Paul
  • Turner, Jessica A.
  • van Erp, Theo
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Focusing on Comorbidity-A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders

  • Fortea, Lydia|||0000-0001-6778-2316
  • Albajes-Eizagirre, Anton
  • Yao, Yuan-Wei
  • Soler, Edu
  • Verdolini, Norma|||0000-0001-9488-2881
  • Hauson, Alexander O.
  • Fortea, Adriana
  • Madero, Santiago|||0000-0002-1123-4211
  • Solanes, Aleix|||0000-0002-2491-200X
  • Wollman, Scott C.
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Wise, Toby
  • Lukito, Steve
  • Picó-Pérez, Maria|||0000-0002-1573-2445
  • Carlisi, Christina
  • Zhang, JinTao
  • Pan, PingLei
  • Farré-Colomés, Álvar
  • Arnone, Danilo
  • Kempton, Matthew|||0000-0003-3541-9947
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Rubia, Katya|||0000-0002-1410-7701
  • Norman, Luke
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Mataix-Cols, David|||0000-0002-4545-0924
  • Valentí, Marc
  • Via, Esther|||0000-0002-2331-3232
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Solmi, Marco|||0000-0003-4877-7233
  • Shin, Jae I.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
In mental health, comorbidities are the norm rather than the exception. However, current meta-analytic methods for summarizing the neural correlates of mental disorders do not consider comorbidities, reducing them to a source of noise and bias rather than benefitting from their valuable information. We describe and validate a novel neuroimaging meta-analytic approach that focuses on comorbidities. In addition, we present the protocol for a meta-analysis of all major mental disorders and their comorbidities. The novel approach consists of a modification of Seed-based d Mapping-with Permutation of Subject Images (SDM-PSI) in which the linear models have no intercept. As in previous SDM meta-analyses, the dependent variable is the brain anatomical difference between patients and controls in a voxel. However, there is no primary disorder, and the independent variables are the percentages of patients with each disorder and each pair of potentially comorbid disorders. We use simulations to validate and provide an example of this novel approach, which correctly disentangled the abnormalities associated with each disorder and comorbidity. We then describe a protocol for conducting the new meta-analysis of all major mental disorders and their comorbidities. Specifically, we will include all voxel-based morphometry (VBM) studies of mental disorders for which a meta-analysis has already been published, including at least 10 studies. We will use the novel approach to analyze all included studies in two separate single linear models, one for children/adolescents and one for adults. The novel approach is a valid method to focus on comorbidities. The meta-analysis will yield a comprehensive atlas of the neuroanatomy of all major mental disorders and their comorbidities, which we hope might help develop potential diagnostic and therapeutic tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials

  • Taipale, Heidi
  • Schneider-Thoma, Johannes
  • Pinzón-Espinosa, Justo|||0000-0002-3084-7793
  • Radua, Joaquim|||0000-0003-1240-5438
  • Efthimiou, Orestis
  • Vinkers, Christiaan H.|||0000-0003-3698-0744
  • Mittendorfer-Rutz, Ellenor
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Pintor Pérez, Luis|||0000-0002-8730-7296
  • Tanskanen, Antti
  • Tomlinson, Anneka
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Cipriani, Andrea
  • Vieta, Eduard|||0000-0002-0548-0053
  • Leucht, Stefan
  • Tiihonen, Jari
  • Luykx, Jurjen J.|||0000-0002-6439-2774
This cohort study quantifies the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in randomized clinical trials and explores whether clinical outcomes differ between eligible and ineligible individuals. What percentage of patients with schizophrenia in the real world are represented in randomized clinical trials (RCTs) and do their outcomes differ from those not represented in RCTs? In this study of 25 259 real-world individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden, about a fifth were represented in RCTs and their outcomes were better than of those individuals with schizophrenia not meeting RCT inclusion criteria. Future research should consider the heterogeneity of individuals with schizophrenia and the patient groups typically ineligible for participation; RCTs may become more inclusive by representing a broader spectrum of individuals with schizophrenia and by targeting specific currently underrepresented groups. Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent only a part of the real-world population (ie, unselected patients seen in everyday clinical practice), which may result in an efficacy-effectiveness gap. To quantify the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in RCTs, and to explore whether clinical outcomes differ between eligible and ineligible individuals. This study applied eligibility criteria typically used in RCTs for relapse prevention in schizophrenia spectrum disorders to real-world populations. Individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden were identified. Individuals who had used antipsychotics continuously for 12 weeks in outpatient care were selected. Individuals were followed up for up to 1 year while they were receiving maintenance treatment with any second-generation antipsychotic (excluding clozapine). Follow-up was censored at treatment discontinuation, initiation of add-on antipsychotics, death, and end of database linkage. Proportions of RCT-ineligible individuals with schizophrenia spectrum disorders owing to any and specific RCT exclusion criteria. The risk of hospitalization due to psychosis within 1-year follow-up in ineligible vs eligible persons were compared using hazard ratios (HR) and corresponding 95% CIs. The mean (SD) age in the Finnish cohort (n = 17 801) was 47.5 (13.8) years and 8972 (50.4%) were women; the mean (SD) age in the Swedish cohort (n = 7458) was 44.8 (12.5) years and 3344 (44.8%) were women. A total of 20 060 individuals (79%) with schizophrenia spectrum disorders would be ineligible for RCTs (Finnish cohort: 14 221 of 17 801 [79.9%]; Swedish cohort: 5839 of 7458 [78.3%]). Most frequent reasons for ineligibility were serious somatic comorbidities and concomitant antidepressant/mood stabilizer use. Risks of hospitalization due to psychosis was higher among ineligible than eligible individuals (Finnish cohort: 18.4% vs 17.2%; HR, 1.14 [95% CI, 1.04-1.24]; Swedish cohort: 20.1% vs 14.8%; HR, 1.47 [95% CI, 1.28-1.92]). The largest risks of hospitalization due to psychosis were observed in individuals ineligible owing to treatment resistance, tardive dyskinesia, and history of suicide attempts. Finally, with more ineligibility criteria met, larger risks of hospitalization due to psychosis were observed in both countries. RCTs may represent only about a fifth of real-world individuals with schizophrenia spectrum disorders. Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher risks of admission due to psychosis while receiving maintenance treatment than RCT-eligible patients. These findings set the stage for future studies targeting real-world populations currently not represented by RCTs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix|||0000-0002-2491-200X
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Arango, Celso|||0000-0003-3382-4754
  • Vieta, Eduard|||0000-0002-0548-0053
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Albacete, Auria|||0000-0003-4156-4972
  • Giné Serven, Eloi|||0000-0002-3130-5566
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  • Solana, Elisabeth|||0000-0001-7973-2439
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Lopez-Soley, Elisabet
  • Radua, Joaquim|||0000-0003-1240-5438
  • Sola-Valls, Nuria
  • Montejo, Carmen
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Pulido-Valdeolivas, Irene|||0000-0003-0188-2458
  • Sepúlveda, Maria
  • Andorra, Magí
  • Berenguer, Juan|||0000-0001-8541-8200
  • Villoslada, P.|||0000-0002-8735-6119
  • Martinez-Lapiscina, E.H.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Saiz, Albert|||0000-0002-5793-8791
  • Fortea, Juan|||0000-0002-1340-638X
  • Llufriu, Sara|||0000-0003-4273-9121
The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.